276 related articles for article (PubMed ID: 26832797)
1. T-Type Ca2+ Channel Inhibition Sensitizes Ovarian Cancer to Carboplatin.
Dziegielewska B; Casarez EV; Yang WZ; Gray LS; Dziegielewski J; Slack-Davis JK
Mol Cancer Ther; 2016 Mar; 15(3):460-70. PubMed ID: 26832797
[TBL] [Abstract][Full Text] [Related]
2. Blockade of T-type Ca(2+) channels inhibits human ovarian cancer cell proliferation.
Li W; Zhang SL; Wang N; Zhang BB; Li M
Cancer Invest; 2011 Jun; 29(5):339-46. PubMed ID: 21438841
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of T-type calcium channels disrupts Akt signaling and promotes apoptosis in glioblastoma cells.
Valerie NC; Dziegielewska B; Hosing AS; Augustin E; Gray LS; Brautigan DL; Larner JM; Dziegielewski J
Biochem Pharmacol; 2013 Apr; 85(7):888-97. PubMed ID: 23287412
[TBL] [Abstract][Full Text] [Related]
4. Multifunctional Polymeric Micelles Co-loaded with Anti-Survivin siRNA and Paclitaxel Overcome Drug Resistance in an Animal Model of Ovarian Cancer.
Salzano G; Navarro G; Trivedi MS; De Rosa G; Torchilin VP
Mol Cancer Ther; 2015 Apr; 14(4):1075-84. PubMed ID: 25657335
[TBL] [Abstract][Full Text] [Related]
5. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
6. Dual mTORC1/2 Inhibition as a Novel Strategy for the Resensitization and Treatment of Platinum-Resistant Ovarian Cancer.
Musa F; Alard A; David-West G; Curtin JP; Blank SV; Schneider RJ
Mol Cancer Ther; 2016 Jul; 15(7):1557-67. PubMed ID: 27196780
[TBL] [Abstract][Full Text] [Related]
7. BRCA1-IRIS inactivation sensitizes ovarian tumors to cisplatin.
Paul BT; Blanchard Z; Ridgway M; ElShamy WM
Oncogene; 2015 Jun; 34(23):3036-52. PubMed ID: 25132263
[TBL] [Abstract][Full Text] [Related]
8. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Ca
Liu Z; Zhang S; Hou F; Zhang C; Gao J; Wang K
Int J Cancer; 2019 May; 144(9):2215-2226. PubMed ID: 30243029
[TBL] [Abstract][Full Text] [Related]
10. T-type calcium channel antagonists, mibefradil and NNC-55-0396 inhibit cell proliferation and induce cell apoptosis in leukemia cell lines.
Huang W; Lu C; Wu Y; Ouyang S; Chen Y
J Exp Clin Cancer Res; 2015 May; 34(1):54. PubMed ID: 25989794
[TBL] [Abstract][Full Text] [Related]
11. Forkhead Box Protein C2 (FOXC2) Promotes the Resistance of Human Ovarian Cancer Cells to Cisplatin In Vitro and In Vivo.
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(1):242-52. PubMed ID: 27336949
[TBL] [Abstract][Full Text] [Related]
12. MiR-205 and miR-218 expression is associated with carboplatin chemoresistance and regulation of apoptosis via Mcl-1 and Survivin in lung cancer cells.
Zarogoulidis P; Petanidis S; Kioseoglou E; Domvri K; Anestakis D; Zarogoulidis K
Cell Signal; 2015 Aug; 27(8):1576-88. PubMed ID: 25917317
[TBL] [Abstract][Full Text] [Related]
13. Gemcitabine as a molecular targeting agent that blocks the Akt cascade in platinum-resistant ovarian cancer.
Kawaguchi H; Terai Y; Tanabe A; Sasaki H; Takai M; Fujiwara S; Ashihara K; Tanaka Y; Tanaka T; Tsunetoh S; Kanemura M; Ohmichi M
J Ovarian Res; 2014 Apr; 7():38. PubMed ID: 24713296
[TBL] [Abstract][Full Text] [Related]
14. Cyclin-Dependent Kinase 11 (CDK11) Is Required for Ovarian Cancer Cell Growth In Vitro and In Vivo, and Its Inhibition Causes Apoptosis and Sensitizes Cells to Paclitaxel.
Liu X; Gao Y; Shen J; Yang W; Choy E; Mankin H; Hornicek FJ; Duan Z
Mol Cancer Ther; 2016 Jul; 15(7):1691-701. PubMed ID: 27207777
[TBL] [Abstract][Full Text] [Related]
15. NO signaling confers cytoprotectivity through the survivin network in ovarian carcinomas.
Engels K; Knauer SK; Loibl S; Fetz V; Harter P; Schweitzer A; Fisseler-Eckhoff A; Kommoss F; Hanker L; Nekljudova V; Hermanns I; Kleinert H; Mann W; du Bois A; Stauber RH
Cancer Res; 2008 Jul; 68(13):5159-66. PubMed ID: 18593915
[TBL] [Abstract][Full Text] [Related]
16. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
[TBL] [Abstract][Full Text] [Related]
17. Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer.
Vivas-Mejia PE; Rodriguez-Aguayo C; Han HD; Shahzad MM; Valiyeva F; Shibayama M; Chavez-Reyes A; Sood AK; Lopez-Berestein G
Clin Cancer Res; 2011 Jun; 17(11):3716-26. PubMed ID: 21512144
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
Westfall SD; Skinner MK
Mol Cancer Ther; 2005 Nov; 4(11):1764-71. PubMed ID: 16275998
[TBL] [Abstract][Full Text] [Related]
19. Knockdown of platinum-induced growth differentiation factor 15 abrogates p27-mediated tumor growth delay in the chemoresistant ovarian cancer model A2780cis.
Meier JC; Haendler B; Seidel H; Groth P; Adams R; Ziegelbauer K; Kreft B; Beckmann G; Sommer A; Kopitz C
Cancer Med; 2015 Feb; 4(2):253-67. PubMed ID: 25490861
[TBL] [Abstract][Full Text] [Related]
20. Survivin status affects prognosis and chemosensitivity in epithelial ovarian cancer.
Chen L; Liang L; Yan X; Liu N; Gong L; Pan S; Lin F; Zhang Q; Zhao H; Zheng F
Int J Gynecol Cancer; 2013 Feb; 23(2):256-63. PubMed ID: 23358177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]